Efficiency of Cell Therapy in Liver Cirrhosis.

Autor: Shevela EY; Research Institute of Clinical Immunology, Novosibirsk, Russia. ct_lab@mail.ru., Starostina NM; Research Institute of Clinical Immunology, Novosibirsk, Russia., Pal'tsev AI; Research Institute of Clinical Immunology, Novosibirsk, Russia., Shipunov MV; Research Institute of Clinical Immunology, Novosibirsk, Russia., Zheltova OI; Research Institute of Clinical Immunology, Novosibirsk, Russia., Meledina IV; Research Institute of Clinical Immunology, Novosibirsk, Russia., Khvan LA; Research Institute of Clinical Immunology, Novosibirsk, Russia., Leplina OY; Research Institute of Clinical Immunology, Novosibirsk, Russia., Ostanin AA; Research Institute of Clinical Immunology, Novosibirsk, Russia., Chernykh ER; Research Institute of Clinical Immunology, Novosibirsk, Russia., Kozlov VA; Research Institute of Clinical Immunology, Novosibirsk, Russia.
Jazyk: angličtina
Zdroj: Bulletin of experimental biology and medicine [Bull Exp Biol Med] 2016 Feb; Vol. 160 (4), pp. 542-7. Date of Electronic Publication: 2016 Feb 23.
DOI: 10.1007/s10517-016-3215-7
Abstrakt: We studied safety and clinical efficacy of transplantation of autologous bone marrow cell in complex therapy of 158 patients with chronic hepatitis and cirrhosis of the liver. The efficiency of cell therapy was assessed in 12 months after single injection of the cells. The positive response (alleviation of liver cirrhosis or stabilization of the pathological process) was observed in 70% cases. The efficacy of therapy correlated with the severity and etiology of the disease and was maximum in patients with Child-Pugh class A (in 82.5% cases) and class B liver cirrhosis (in 79% cases); in patients with class C liver cirrhosis, the positive response was achieved in 42.5% cases. In 39 patients, ultrasonic examination performed in 3 years after transplantation revealed no focal lesions or ectopic ossification foci.
Databáze: MEDLINE
načítá se...